Jakobsen Anders K M, Spindler Karen-Lise G
Institute of Regional Health Services, University of Southern Denmark, Department of Oncology, Vejle University Hospital, 7100, Vejle, Denmark.
Department of Oncology, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Aarhus University, Denmark.
Eur J Cancer. 2023 Feb;180:180-183. doi: 10.1016/j.ejca.2022.11.039. Epub 2022 Dec 17.
In the metastatic setting, most decisions during systemic palliative therapies are based on the imaging-based Response Evaluation Criteria in Solid Tumors (RECIST), which is, however, known to be a suboptimal surrogate marker for the clinical outcome overall survival. Over the past decade, research has brought focus to the potential of circulating tumour DNA in cancer. However, at present, there is no generally accepted classification of quantitative changes during the treatment course, and prospective investigations can therefore not be validated. We here propose, for the first time, a response classification based on circulating tumour DNA measurements and its confidence intervals, a "ctDNA-RECIST" that has proven valuable in retrospective studies and goes along with the conventional RECIST classification. We aim to raise the topic for discussion and to encourage analyses of ctDNA data along this line.
在转移性疾病的情况下，全身姑息治疗期间的大多数决策是基于实体瘤的基于影像的疗效评价标准（RECIST），然而，众所周知，这对于总体生存的临床结局而言是一个次优的替代标志物。在过去十年中，研究聚焦于循环肿瘤DNA在癌症中的潜力。然而，目前对于治疗过程中的定量变化尚无普遍接受的分类方法，因此前瞻性研究无法得到验证。我们在此首次提出一种基于循环肿瘤DNA测量及其置信区间的疗效分类方法，即“ctDNA-RECIST”，它在回顾性研究中已被证明具有价值，并且与传统的RECIST分类方法一致。我们旨在提出该话题以供讨论，并鼓励沿此思路对ctDNA数据进行分析。
